Prevalence and risk factors of anxiety and depression among patients with breast cancer: a protocol for systematic review and meta-analysis

Jie Li,1,† Feng Zhang,1,† Wenchun Wang,2 Rizhao Pang,2 Jiancheng Liu,2 Qiuhong Man,3 Anren Zhang4

ABSTRACT

Background Patients with breast cancer often experience severe psychological distress, especially anxiety and depression, leading to poorer quality of life, shortened survival time and increased mortality. The objective of the review will be to summarise data on the prevalence and risk factors of anxiety and depression in patients with breast cancer.

Methods and analysis Two reviewers will be applied in seven databases, including Web of Science, PubMed, EMBASE, Wan Fang Data Knowledge Service Platform, Chinese Biomedical Literature Database, Chinese Scientific Journal Database (VIP database), China National Knowledge Infrastructure and for studies on the prevalence and risk factors of depression in patients with breast cancer, which should be published from inception to Feb 2020 in English, Chinese, French and Spanish. The selection of studies, data extraction and risk of bias assessment will be done independently by two reviewers. Data synthesis will be carried out using RevMan V.5.3 software. The heterogeneity will be determined by the I² test. Publication bias will be evaluated by generating a funnel plot and performing the Begg and Egger test. The quality of the systematic review will be assessed using the Grading of Recommendations Assessment, Development and Evaluation Tool criteria.

Ethics and dissemination No ethical approval is required. This protocol will not involve individual patient information and endangering participant rights. The results will be reported in a peer-reviewed journal or disseminated in relevant conferences.

OSF registration number DOI 10.17605/OSF.IO/D6A4P.

INTRODUCTION

Breast cancer in women is increasing worldwide. The Cancer Statistics1 produced the three most common cancers, including breast cancer, lung cancer and colorectal cancer, accounting for 50% of all new diagnoses. Prevalence of breast cancer alone accounts for 30% of female cancers and has been listed as the most frequent cancer diagnosis of female malignancy. It is known as global cancer statistics; 2 088 849 new cases were reported in 2018.

Published epidemiological reports around the world3 show that there is a significant increase in the death rate from breast cancer over the past two decades. Approximately 0.5 million people worldwide die from metastatic breast cancer every year even after receiving many therapies. Patients with breast cancer suffer from psychological and physical cancer-related stressors, which may affect patients for many years after treatment.4 Women with breast cancer may suffer from treatment-related side effects, such as surgical trauma, scarring, mastectomy and lymphedema. According to the medical data5,6 these effects will easily lead to body image distortion, sexual dysfunction/intimacy problems as well as low self-esteem. Compared with the general population, when these patients are diagnosed with breast cancer, these effects will cause nearly 50% of patients with breast cancer to experience more considerable psychological distress, such as depression and anxiety, the prevalence of depression and anxiety in the
year after diagnosis is around twice as high as in the general female population. Besides, lack of intimate confiding support will also lead to chronic depression and anxiety. The quality of life of patients with psychological symptoms is poor and the risk should not be ignored. The depressive symptoms in patients with breast cancer can lead to physical deterioration and increased mortality. Early symptoms in patients with breast cancer can lead to depression, while others have found that the risk of depression can reduce the risk of depression. For study selection, we will exclude cross-sectional, cohort studies, case–control studies, case reports, case series, opinion papers, qualitative research, letters to the editor, comments, conference proceedings, policy documents, reviews and meta-analyses, study protocols without baseline data and animal studies.

METHODS
This study consists the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Inclusion criteria for study selection
Types of studies
Observational studies with available data on the prevalence and risk factors associated with anxiety and depression among patients with breast cancer will be considered. For study selection, we will exclude cross-sectional, cohort studies, case–control studies, case reports, case series, opinion papers, qualitative research, letters to the editor, comments, conference proceedings, policy documents, reviews and meta-analyses, study protocols without baseline data and animal studies.

Types of patients
Study population inclusion criteria will be all patients diagnosed with breast cancer, regardless of demographic age, race and education status.

Types of outcome measures
(1) Prevalence of anxiety and depression among patients with breast cancer; (2) Risk factors associated with anxiety and depression in patients with breast cancer and (3) The strength of the correlation between each risk factor and anxiety and depression.

Search methods for the identification of studies
Data sources
The following databases will be used: Web of Science, PubMed, EMBASE, Wan Fang Data Knowledge Service Platform, Chinese Biomedical Literature Database, Chinese Scientific Journal Database (VIP database), China National Knowledge Infrastructure. We will also conduct unpublished academic research data, contacting authors in the field for information. Two systematic reviews will be carried out from inception to February 2020. The reference lists of review articles will be conducted and the following search terms will be used: breast cancer, breast carcinoma, mammary cancer, mammary adenocarcinoma, anxiety, depression and depressive disorder. And we will use the search strategy provided in table 1 for searching the database. The authors will also search relevant trials from Clinical Trials.gov, Google Scholar and WHO International Clinical Trials Registry Platform.

Study selection
Studies imported into Endnote X9 software after deleting duplicates will be independently reviewed by two authors (JL and FZ) based on the exclusion and inclusion criteria. The researcher (WW) will read the full text of relevant articles to confirm the final inclusion of studies. For unclear study, the researcher (RP) will contact the author for details to determine whether this literature would be included. Any disagreement between reviewers will be resolved by discussion or a researcher (LJ). The study screening process is shown in figure 1. The documents selection will be demonstrated on a PRISMA flow chart.

Risk of bias assessment
The risk of bias will be assessed applying the Cochrane’s ‘Risk of bias’ tool. The quality of the included studies will be assessed independently by two authors (QM and AZ) at the study and outcome levels. Any disagreements will be settled by discussion or with the arbitrament of the third author (LJ). In this study, we will use the Newcastle-Ottawa Scale to evaluate the quality of studies. This scale is a quality assessment tool for non-randomised controlled trials, with scores ranging from 0 to 9; scores of 0–4 and 5–9 mean low quality and high quality, respectively.

Statistical collection and analysis
Data extraction and management
Extracted information include the first author’s name, date of publication, journal, country and region, sample size (N and male/female), duration of the study, baseline age, diagnostic criteria for breast cancer and anxiety and depression, incidence of anxiety and depression/mean and SD for anxiety and depression score, variables, OR values, 95% CI, and other relevant data for quality evaluation and risk of bias assessment. And the reasons
for the exclusion of studies while extracting will also be recorded. The extraction of possible risk factors will be included gender, age, occupation, marital status, education level, social support, alcohol status, smoking status, pathological type, cancer clinical stage, disease course and therapy method. The extracted variables will be adjusted during the process, as it is likely that more and more variables that need to be included will turn up. Data collection will be done by two reviewers (JL and FZ) independently using Review Manager software. And if they are inconsistent in the process, they will discuss the results. A third reviewer will be consulted to resolve the doubts. For unclear details, the researchers will contact the corresponding authors by email for detailed information.

Measurements of prevalence and risk factors
RevMan V.5.3 will be used to calculate the OR values and 95% CIs of the reported risk factors for anxiety and depression in breast cancer. When the CI for the OR does not include 1, it is considered statistically significant. The prevalence estimates reported by the individual studies will be extracted or converted into prevalence percentages, and their respective SEs will be calculated. For the anxiety and depression scores, standardised mean difference will be used for analysis. We will use the Freeman-Tukey double arcsine transformation to stabilise the variance of study-specific prevalence. The prevalence of each study will be recalculated to confirm numerators and denominators, and adjustments as necessary.

Assessment of heterogeneity
The I² test will be used to determine the extent of heterogeneity. When the I² value is less than 50%, the fixed-effects model will be used. If the I² value is higher than 50%, the random-effects model will be used. In this study, factors of high heterogeneity will be removed one by one to identify the source of any observed heterogeneity. The causes of heterogeneity may include differences in study design, statistical methods and participants.

Data synthesis
We will use RevMan V.5.3 software for analysis. Meta-analysis will be performed when the heterogeneity is low or the source could be found, although heterogeneity is high. A systematic narrative synthesis will be conducted if it is impossible to complete any meta-analysis. If there is significant heterogeneity, we will use the subgroup analysis.

Subgroup analysis
Subgroup analysis will be done when data are available. The groups may be designed based on country or region,
diagnostic criteria for anxiety and depression, bias score, time since diagnosis (long-term vs short-term survivors), severity/staging of breast cancer and study design.

**Meta-regression analysis**

Meta-regression analysis will be used to evaluate important factors (gender, age, occupation, marital status, education level, social support, alcohol status, smoking status, pathological type, cancer clinical stage, disease course and therapy method) on our study, which may explain heterogeneity across studies in the pooled effect size.

**Assessment of reporting biases**

Funnel plots will be used to assess publication bias. We will evaluate publication bias by performing the Begg’s and Egger’s tests. The significant p value (<0.05) indicates the existence of publication bias.

**Quality control of the systematic review and meta-analysis**

The methodological quality of the systematic review will be evaluated using the Measurement Tool to Assess Systematic Reviews. The Grading of Recommendations Assessment, Development and Evaluation will also be used to evaluate the strength of evidence produced by the systematic review (JL and FZ).

**DISCUSSION**

This study will review current researches to provide effective evidence on the risk factors related to depression and anxiety, and the results of systematic review and meta-analysis will provide significant help in identifying high-risk groups. These unified risk factors of depression will be screen out to advise on the management of emotional issues for patients. There may be some limitations to this review. First, a limitation will be the high heterogeneity studies may not be appropriate to be used in meta-analysis. Second, there may be heterogeneity in the diagnostic criteria for different types of anxiety and depression, as well as in the staging of cancer and depression. Different measurements and tools might lead to inconsistent levels of outcomes.

**Contributors**

JL and FZ will identify eligible studies after reading titles and abstracts. WW will read the full texts to perform further selection. Several studies from different opinions will be determined by the RP. Data will be extracted from the original reports by LJ. The assessment of the risk of bias will be carried out by QM, AZ and JL. Any discrepancies will be resolved by discussion with a third party. JL conceived the review protocol and drafted the manuscript. FZ will monitor each procedure of the review. All authors read and approved the publication of the protocol.

**Funding**

This work is supported by the National Natural Science Foundation of China (81973927).

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not required.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Jie Li https://orcid.org/0000-0002-6375-5123

Feng Zhang https://orcid.org/0000-0002-5557-0129

**REFERENCES**

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.

2 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

3 Azamjah N, Soitan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. Asian Pac J Cancer Prev 2019;20:2015–20.

4 Pinquart M, Frohlich C, Silbereisen RK. Cancer patients’ perceptions of positive and negative illness-related changes. J Health Psychol 2007;12:907–21.

5 Institute of Medicine US Cancer., Policy Board. Meeting psychosocial needs of women with breast cancer. Washington, DC: National Academies Press (US), 2004.

6 Prates ACL, Freitas-Junior R, Prates MFO, et al. Influence of body image in women undergoing treatment for breast cancer. Rev Bras Ginecol Obstet 2017;39:175–83.

7 Okamura H, Watanabe T, Narabayashi M, et al. Psychological distress following first recurrence of disease in patients with breast cancer: prevalence and risk factors. Breast Cancer Res Treat 2000;61:131–7.

8 Burgess C, Cornelius V, Love S, et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005;330:702.

9 Kang D-H, Park N-J, McDermott T. Cancer-Specific stress and mood disturbance: implications for symptom perception, quality of life, and immune response in women shortly after diagnosis of breast cancer. J Nurs 2012;29:621–7.

10 Fann JR, Thomas-Rich AM, Katon WJ, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 2008;30:112–26.

11 Perry S, Kowalski TL, Chang C-H. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 2007;5:24.

12 Liang X, Margolis KL, Hendryx M, et al. Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. Cancer 2017;123:3107–15.

13 Jacob L, Kalder M, Kostev K. Incidence of depression and anxiety among women newly diagnosed with breast or genital organ cancer in Germany. Psychooncology 2017;26:1535–40.

14 Cvetkovic J, Nenadovic M. Depression in breast cancer patients. Psychiatry Res 2016;240:343–7.

15 McFarland DC, Shaffer KM, Tiersten A, et al. Physical symptom burden and its association with distress, anxiety, and depression in breast cancer. Psychosomatics 2018;59:464–71.

16 Burgess CC, Ramirez AJ, Richards MA, et al. Does the method of detection of breast cancer affect subsequent psychiatric morbidity? Eur J Cancer 2002;38:1622–5.

17 Kiebert GM, de Haes JC, van de Velde CJ. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol 1991;9:1059–70.

18 Lee MS, Love SB, Mitchell JB, et al. Mastectomy or conservation for early breast cancer: psychological morbidity. Eur J Cancer 1992;28A:1340–4.

19 Hughson AV, Cooper AF, Mcardle CS, et al. Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. Br Med J 1996;293:1299–7.

20 Dean C. Psychiatric morbidity following mastectomy: preoperative predictors and types of illness. J Psychosom Res 1987;31:385–92.